BSP Pharmaceuticals, a CDMO of drug substances and drug products, has announced a multi-year, $576-million expansion for cytotoxic and non-cytotoxic products. Anna Maria Braca, General Counsel & Vice President, Strategic Business Development, BSP Pharmaceuticals, outlined the expansion plan at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week. 

BSP Pharmaceuticals announced an investment totaling EUR 530 million ($576 million) to expand its site in Latina, Italy, designed for the manufacturing of cytotoxic and non-cytotoxic innovative products. The investments begin in 2024 and will be completed by the end of 2028. 

The new cycle of investment includes two additional conjugation suites of 6,500 g/batch monoclonal antibody (mAb) scale and two new sterile suites in full containment for sterile liquid and lyo vials with related clean utilities for manufacturing of cytotoxic compounds.

Three additional sterile suites in full containment are to be built for manufacturing sterile liquid and lyo vials in the non-cytotoxic site for biologics and small-molecule innovative molecules for immuno-oncology and immunotherapy.

An expansion of the company’s warehouse will increase cold-chain capacity for biologics with the installation of additional refrigerated and deep-frozen storage. Additionally, expansion of chemical, biochemical, and microbiological laboratories will complete the organic growth of the site.

Upon completion of this cycle of investment during the term 2024 and 2028, BSP will be able to offer up to approximately 2,800 Kg mAb/year for manufacturing biological drug substances, 52 million injectable units/year for cytotoxic drug products, and 103 million injectable units/year for non-cytotoxic drug products.